Genomic profiling by whole-genome single nucleotide polymorphism arrays in Wilms tumor and association with relapse

Genes Chromosomes and Cancer

Volumn 51, Issue 7, 2012, Pages 644-653

  Perotti, Daniela ^a   Spreafico, Filippo ^a   Torri, Federica ^b   Gamba, Beatrice ^a   D'Adamo, Pio ^c   Pizzamiglio, Sara ^a   Terenziani, Monica ^a   Catania, Serena ^a   Collini, Paola ^a   Nantron, Marilina ^d   Pession, Andrea ^e   Bianchi, Maurizio ^f   Indolfi, Paolo ^g   D'Angelo, Paolo ^h   Fossati Bellani, Franca ⁱ   Verderio, Paolo ^a   Macciardi, Fabio ^b   Radice, Paolo ^a,j  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TRIESTE   (Italy)

^d G GASLINI INSTITUTE   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h ARNAS Ospedali Civico di Cristina e Benfratelli   (Italy)

ⁱ Section of Milan   (Italy)

^j FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ALLELE; ARTICLE; CANCER RELAPSE; CANCER STAGING; CHILD; CHROMOSOME 14Q; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 3P; COPY NUMBER VARIATION; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROBLASTOMA; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ALLELIC IMBALANCE; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; DNA COPY NUMBER VARIATIONS; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RECURRENCE; WILMS TUMOR;

EID: 84860672169     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.21951     Document Type: Article

References (48)

1. Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ, Ferre F, Bourque C, Burke CJ, Turner L, Uong A, Johnson LA, Beroukhim R, Mermel CH, Loda M, it-Si-Ali S, Garraway LA, Young RA, Zon LI. 2011. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 471: 513-517.
2. Chen Z, Liu Z, Li W, Qu K, Deng X, Varma MG, Fichera A, Pigazzi A, Garcia-Aguilar J. 2011. Chromosomal copy number alterations are associated with tumor response to chemoradiation in locally advanced rectal cancer. Genes Chromosomes Cancer 50: 689-699.
3. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH, Fishman D, Gray JW, Mills GB. 2004. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 10: 1251-1256.
4. Darvishi K. 2010. Application of Nexus copy number software for CNV detection and analysis. Curr Protoc Hum Genet 4: 4.14.1-4.14.28.
5. de Kraker J, Graf N, van TH, Pein F, Sandstedt B, Godzinski J, Tournade MF. 2004. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): A randomised controlled trial. Lancet 364: 1229-1235.
6. Dellinger AE, Saw SM, Goh LK, Seielstad M, Young TL, Li YJ. 2010. Comparative analyses of seven algorithms for copy number variant identification from single nucleotide polymorphism arrays. Nucleic Acids Res 38: e105.
7. Donovan MJ, Hempstead B, Huber LJ, Kaplan D, Tsoulfas P, Chao M, Parada L, Schofield D. 1994. Identification of the neurotrophin receptors p75 and trk in a series of Wilms' tumors. Am J Pathol 145: 792-801.
8. Drake KM, Ruteshouser EC, Natrajan R, Harbor P, Wegert J, Gessler M, Pritchard-Jones K, Grundy P, Dome J, Huff V, Jones C, Aldred MA. 2009. Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562. Clin Cancer Res 15: 5985-5992.
9. Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, Park E, Kim YM, Hofmann WK, Herzog S, Jumaa H, Koeffler HP, Yu JJ, Heisterkamp N, Graeber TG, Wu H, Ye BH, Melnick A, Muschen M. 2011. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 473: 384-388.
10. Faria P, Beckwith JB, Mishra K, Zuppan C, Weeks DA, Breslow N, Green DM. 1996. Focal versus diffuse anaplasia in Wilms tumor-new definitions with prognostic significance: A report from the National Wilms Tumor Study Group. Am J Surg Pathol 20: 909-920.
11. Green DM, Breslow NE, D'Angio GJ. 1993. The treatment of children with unilateral Wilms' tumor. J Clin Oncol 11: 1009-1010.
12. Green DM, Breslow NE, Beckwith JB, Finklestein JZ, Grundy PE, Thomas PR, Kim T, Shochat SJ, Haase GM, Ritchey ML, Kelalis PP, D'Angio GJ. 1998. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 16: 237-245.
13. Green DM, Breslow NE, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Perlman E, Donaldson M, Grundy PE, Weetman R, Coppes MJ, Malogolowkin M, Shearer P, Coccia P, Kletzel M, Thomas PR, Macklis R, Tomlinson G, Huff V, Newbury R, Weeks D. 2001. Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: A report from the National Wilms' Tumor Study Group. J Clin Oncol 19: 3719-3724.
14. Grundy PE, Telzerow PE, Breslow N, Moksness J, Huff V, Paterson MC. 1994. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res 54: 2331-2333.
15. Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Donaldson M, Coppes MJ, Malogolowkin M, Shearer P, Thomas PR, Macklis R, Tomlinson G, Huff V, Green DM. 2005. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: A report from the National Wilms Tumor Study Group. J Clin Oncol 23: 7312-7321.
16. Halldorsdottir AM, Sander B, Goransson H, Isaksson A, Kimby E, Mansouri M, Rosenquist R, Ehrencrona H. 2011. High-resolution genomic screening in mantle cell lymphoma--specific changes correlate with genomic complexity, the proliferation signature and survival. Genes Chromosomes Cancer 50: 113-121.
17. Hawthorn L, Cowell JK. 2011. Analysis of wilms tumors using SNP mapping array-based comparative genomic hybridization. PLoS One 6: e18941.
18. Hing S, Lu YJ, Summersgill B, King-Underwood L, Nicholson J, Grundy P, Grundy R, Gessler M, Shipley J, Pritchard-Jones K. 2001. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. Am J Pathol 158: 393-398.
19. Huang CC, Gadd S, Breslow N, Cutcliffe C, Sredni ST, Helenowski IB, Dome JS, Grundy PE, Green DM, Fritsch MK, Perlman EJ. 2009. Predicting relapse in favorable histology Wilms tumor using gene expression analysis: A report from the Renal Tumor Committee of the Children's Oncology Group. Clin Cancer Res 15: 1770-1778.
20. Ismail A, Bandla S, Reveiller M, Toia L, Zhou Z, Gooding WE, Kalatskaya I, Stein L, D'Souza M, Litle VR, Peters JH, Pennathur A, Luketich JD, Godfrey TE. 2011. Early G1 cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma. Clin Cancer Res 17: 4513-4522
21. Kaplan EL, Meier P. 1958. Non-parametric estimation from incomplete observations. J Am Stat Assoc 3: 457-481.
22. Klamt B, Schulze M, Thate C, Mares J, Goetz P, Kodet R, Scheurlen W, Weirich A, Graf N, Gessler M. 1998. Allele loss in Wilms tumors of chromosome arms 11q, I6q, and 22q correlates with clinicopathological parameters. Genes Chrom Cancer 22: 287-294
23. Kuefer R, Day KC, Kleer CG, Sabel MS, Hofer MD, Varambally S, Zorn CS, Chinnaiyan AM, Rubin MA, Day ML. 2006. ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia 8: 319-329.
24. Li W, Kessler P, Williams BR. 2005. Transcript profiling of Wilms tumors reveals connections to kidney morphogenesis and expression patterns associated with anaplasia. Oncogene 24: 457-468.
25. Lu YJ, Hing S, Williams R, Pinkerton R, Shipley J, Pritchard-Jones K. 2002. Chromosome 1q expression profiling and relapse in Wilms' tumour. Lancet 360: 385-386.
26. Marubini E, Valsecchi MG. 1995. Analysing Survival Data from Clinical Trials and observational Studies. Chichester, UK: John Wiley & Sons.
27. Matsuzaki H, Wang PH, Hu J, Rava R, Fu GK. 2009. High resolution discovery and confirmation of copy number variants in 90 Yoruba Nigerians. Genome Biol 10: R125.
28. Messahel B, Williams R, Ridolfi A, A'hern R, Warren W, Tinworth L, Hobson R, Al-Saadi R, Whyman G, Brundler MA, Kelsey A, Sebire N, Jones C, Vujanic G, Pritchard-Jones K. 2009. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study. Eur J Cancer 45: 819-826.
29. Mitchell C, Pritchard-Jones K, Shannon R, Hutton C, Stevens S, Machin D, Imeson J, Kelsey A, Vujanic GM, Gornall P, Walker J, Taylor R, Sartori P, Hale J, Levitt G, Messahel B, Middleton H, Grundy R, Pritchard J. 2006. Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: Results of a randomised trial (UKW3) by the UK Children's Cancer Study Group. Eur J Cancer 42: 2554-2562.
30. Natrajan R, Little SE, Reis-Filho JS, Hing L, Messahel B, Grundy PE, Dome JS, Schneider T, Vujanic GM, Pritchard-Jones K, Jones C. 2006a. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors. Clin Cancer Res 12: 7284-7293
31. Natrajan R, Williams RD, Hing SN, Mackay A, Reis-Filho JS, Fenwick K, Iravani M, Valgeirsson H, Grigoriadis A, Langford CF, Dovey O, Gregory SG, Weber BL, Ashworth A, Grundy PE, Pritchard-Jones K, Jones C. 2006b. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol 210: 49-58.
32. Natrajan R, Little SE, Sodha N, Reis-Filho JS, Mackay A, Fenwick K, Ashworth A, Perlman EJ, Dome JS, Grundy PE, Pritchard-Jones K, Jones C. 2007. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. J Pathol 211: 52-59.
33. Ohshima J, Haruta M, Arai Y, Kasai F, Fujiwara Y, Ariga T, Okita H, Fukuzawa M, Hata J, Horie H, Kaneko Y. 2009. Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identified in a 7p21 homozygous deletion region in a Wilms tumor. Genes Chromosomes Cancer 48: 1037-1050.
34. Parris TZ, Danielsson A, Nemes S, Kovacs A, Delle U, Fallenius G, Mollerstrom E, Karlsson P, Helou K. 2010. Clinical implications of gene dosage and gene expression patterns in diploid breast carcinoma. Clin Cancer Res 16: 3860-3874.
35. Paulson V, Chandler G, Rakheja D, Galindo RL, Wilson K, Amatruda JF, Cameron S. 2011. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer 50: 397-408.
36. Perlman EJ. 2005. Pediatric renal tumors: Practical updates for the pathologist. Pediatr Dev Pathol 8: 320-338
37. Perotti D, De Vecchi G, Testi MA, Lualdi E, Modena P, Mondini P, Ravagnani F, Collini P, Di Renzo F, Spreafico F, Terenziani M, Sozzi G, Fossati-Bellani F, Radice P. 2004. Germline mutations of the POU6F2 gene in Wilms tumors with loss of heterozygosity on chromosome 7p14. Hum Mutat 24: 400-407.
38. Pritchard-Jones K, Kelsey A, Vujanic G, Imeson J, Hutton C, Mitchell C. 2003. Older age is an adverse prognostic factor in stage I, favorable histology Wilms' tumor treated with vincristine monochemotherapy: A study by the United Kingdom Children's Cancer Study Group, Wilm's Tumor Working Group. J Clin Oncol 21: 3269-3275.
39. Spreafico F, Fossati-Bellani F. 2006. Wilms' tumor: Past, present and (possibly) future. Expert Rev Anticancer Ther 6: 249-258.
40. Tournade MF, Com-Nougue C, de KJ, Ludwig R, Rey A, Burgers JM, Sandstedt B, Godzinski J, Carli M, Potter R, Zucker JM. 2001. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: Results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. J Clin Oncol 19: 488-500.
41. Veenma D, Beurskens N, Douben H, Eussen B, Noomen P, Govaerts L, Grijseels E, Lequin M, de KR, Tibboel D, de KA, Van OD. 2010. Comparable low-level mosaicism in affected and non affected tissue of a complex CDH patient. PLoS One 5: e15348.
42. Voortman J, Lee JH, Killian JK, Suuriniemi M, Wang Y, Lucchi M, Smith WI, Jr., Meltzer P, Wang Y, Giaccone G. 2010. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci USA 107: 13040-13045.
43. Vujanic GM, Sandstedt B, Harms D, Kelsey A, Leuschner I, de Kraker J. 2002. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol 38: 79-82.
44. Watanabe H, Soejima K, Yasuda H, Kawada I, Nakachi I, Yoda S, Naoki K, Ishizaka A. 2008. Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell Int 8: 15.
45. Williams RD, Al-Saadi R, Chagtai T, Popov S, Messahel B, Sebire N, Gessler M, Wegert J, Graf N, Leuschner I, Hubank M, Jones C, Vujanic G, Pritchard-Jones K. 2010. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Clin Cancer Res 16: 2036-2045.
46. Williams RD, Hing SN, Greer BT, Whiteford CC, Wei JS, Natrajan R, Kelsey A, Rogers S, Campbell C, Pritchard-Jones K, Khan J. 2004. Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines. Genes Chromosomes Cancer 41: 65-79.
47. Wittmann S, Zirn B, Alkassar M, Ambros P, Graf N, Gessler M. 2007. Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis. Genes Chromosomes Cancer 46: 163-170.
48. Yuan E, Li CM, Yamashiro DJ, Kandel J, Thaker H, Murty VV, Tycko B. 2005. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors. Mol Cancer Res 3: 493-502.